Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPT-348
- Development stage
- Preclinical
- Lead developer
- Seaport Therapeutics
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
SPT-348 is a non-hallucinogenic psychoplastogen and serotonin receptor modulator of the lysergamide family, currently under development for the treatment of depression, anxiety, and other neuropsychiatric disorders. It acts as a prodrug of 2-bromo-LSD (bromolysergide; BOL-148), which is a non-selective serotonin receptor modulator and partial agonist at the serotonin 5-HT2A receptor. Unlike LSD, SPT-348 does not induce hallucinogenic effects. The drug utilizes Seaport Therapeutics' proprietary Glyph platform—a triglyceride linker formulation designed to bypass first-pass hepatic metabolism—improving pharmacokinetics and tolerability compared to conventional psychedelics. As of 2025, SPT-348 remains in preclinical or discovery-stage development[1][4][5][7].
- Other names
- Glyph2BLSDGlyph-2BLSDGlyph 2BLSDBOL-148 prodrugBOL148 prodrugBOL 148 prodrug2-bromo-LSD prodrug
02
Targets
HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on SPT-348.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPT-348.